Pulse Biosciences reports 74% avg volume reduction in benign thyroid nodule ablation at 15-22 months

PULSE BIOSCIENCES, INC.

21 patients monitored 15-22 months; average 74% volume reduction of benign thyroid nodules with no regrowth.
100% of patients highly satisfied with cosmetic appearance; 95% highly satisfied overall; no serious adverse events.
Data presented by Prof. Stefano Spiezia at North American Society for Interventional Thyroidology 2026 meeting.
CEO Paul LaViolette said non-cardiac nsPFA plans will be clarified in second half of 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.